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Abstract: Chronic hepatitis C virus (HCV) infection is a major worldwide cause of liver 
disease, including cirrhosis and hepatocellular carcinoma. It is estimated that more than 
170 million individuals are infected with HCV, with three to four million new cases each 
year. The current standard of care, combination treatment with interferon and ribavirin, 
eradicates the virus in only about 50% of chronically infected patients. Notably, neither of 
these drugs directly target HCV. Many new antiviral therapies that specifically target 
hepatitis C (e.g. NS3 protease or NS5B polymerase inhibitors) are therefore in 
development, with a significant number having advanced into clinical trials. The 
nonstructural 4B (NS4B) protein, is among the least characterized of the HCV structural 
and nonstructural proteins and has been subjected to few pharmacological studies. NS4B is 
an integral membrane protein with at least four predicted transmembrane (TM) domains. A 
variety of functions have been postulated for NS4B, such as the ability to induce the 
membranous web replication platform, RNA binding and NTPase activity. This review 
summarizes potential targets within the nonstructural protein NS4B, with a focus on novel 
classes of NS4B inhibitors.  
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1. Introduction 
Hepatitis C virus (HCV) infects an estimated 170 million people around the world [1]. Infection 
often leads to cirrhosis and sometimes to hepatocellular carcinoma [2,3]. No vaccine is currently 
available. The only FDA approved regimen relies on a combination of subcutaneously administered 
pegylated interferon-α (IFN) and oral ribavirin (RBV). These non-HCV specific antivirals, however, 
have limited efficacy. A sustained virologic response (SVR), defined as the absence of HCV RNA in 
the serum six months after the cessation of HCV therapy, can be achieved in only about 42% to 53% 
of patients with HCV genotypes 1 and 4, respectively, and up to 78% to 82% of patients infected with 
HCV genotypes 2 or 3 [4,5]. These genotype specific differences are hypothesized to be due in part to 
the evolution of anti-immune factors [6], which limit the immune response generated by exogenous 
interferon. Furthermore, because the majority of patients infected with HCV in the United States are 
infected with genotype 1, the most treatment-refractory genotype, nearly half of all patients treated for 
HCV with IFN/RBV therapy will fail treatment. IFN/RBV combination therapy is also expensive, and 
results in serious side effects such as fever, fatigue, anemia, leucopenia, thrombocytopenia, and 
depression [7-9].  
For these many reasons, there is an urgent need for HCV-specific antivirals that are both more 
efficacious and tolerable. Furthermore, given the ability of HCV to rapidly acquire resistance to 
antivirals, as has been already shown in multiple clinical trials [10-13], anti-HCV therapeutics that 
target multiple aspects of the HCV-life cycle are expected to be needed in order to control this 
infection—as is currently the case for HIV. The rapidity with which HCV acquires resistance is due in 
part to the fact that the HCV NS5B polymerase lacks a proofreading function, which results in an 
estimated erroneous base substitution rate of ~1 in 10,000 replicated bases [14]. Practically, this means 
that every copy of HCV that is made contains at least one mutation. Given the massive number of 
HCV virions produced in patients chronically infected with HCV (1.3 × 10
12 virions per day) [15], 
every patient is therefore best considered as infected with a population of HCV quasi-species [16,17]. 
Such quasi-species, when under selective antiviral pressure, lead to the emergence of resistant strains.  
Therefore, a collection of well-tolerated HCV antivirals that target multiple steps of the HCV life 
cycle, and which thereby can overwhelm the ability of such quasi-species to adapt, represents the 
idealized goal for future HCV drug development. These agents are termed “specifically targeted 
antiviral therapy for HCV” or STAT-C drugs [18,19]. Among the most promising new anti-HCV 
agents in clinical development are those that target the NS3 protease, the NS5A protein, the   
RNA-polymerase NS5B, and compounds that directly inhibit HCV replication through interaction with 
host cell proteins (see [20-23] for more in depth reviews of these agents). Another new promising 
strategy consists of targeting the NS4B protein. This review focuses on the recent developments of 




2. Important features of NS4B  
NS4B is a relatively poorly characterized 27 kDa protein with at least four predicted 
transmembrane (TM) domains [24-26]
 (Figure 1). As a consequence of polyprotein processing by the 
NS3-4A protease, the N- and C-terminal parts of NS4B are believed to be oriented towards the 
cytosolic side of the endoplasmic reticulum (ER) membrane. An amphipathic helix (AH), a helix in 
which one side is hydrophobic and the other hydrophilic, is located within the first 27 amino acids of 
NS4B and designated AH1 [27]. When N-terminally fused to a construct containing GFP, AH1 was 
shown to mediate membrane association, and point mutations disrupting its hydrophobic face 
abrogated membrane association [27]. Of note, fusion of amino acids 1 to 29 or 1 to 40 of NS4B did 
not confer membrane association [28], possibly reflecting differences in the respective expression 
constructs. Insertion of artificial glycosylation acceptor sites at various positions in NS4B yielded 
evidence in support of the predicted ER luminal loops around amino acid positions 112 and 161 
[24,29]. In addition, a fraction of NS4B may acquire a fifth TM domain, postulated to result from  
post-translational translocation of the N-terminal domain into the ER lumen (see Figure 1) [29].  
Recently, we and others have identified a second AH (AH2) immediately following AH1 (Figure 1) 
that is sufficient to confer tight membrane association and is required for viral replication [28,30,31]. It 
is suggested that this amphipathic -helix has the potential to traverse the phospholipid bilayer as a 
transmembrane domain [28]. We have shown that AH2 can both oligomerize with itself and 
specifically mediate lipid vesicle aggregation [30]—a function that might be relevant for the role of 
NS4B in forming the membranous web replication platform [32] (discussed below). A variety of 
biophysical measurements have confirmed the predicted helical nature of AH1 [33] and AH2 [28,30]. 
Secondary structure analyses have also predicted two helices in the C-terminal portion of NS4B. 
The first of these C-terminal helices (H1) is composed of amino acids ~200–213 and is highly 
conserved among HCV genotypes. The second helix (H2), also confirmed by CD [31], is composed of 
amino acids ~229–253 and is more variable. H2 also has an amphipathic structure, mediates membrane 
association, and is involved in the formation of functional HCV replication complexes 
[26,28,31,32,34-38]. NS4B has also been shown to interact with itself, suggesting an ability to form 
homo-multimers [39,40]. Finally, NS4B has been shown to be palmitoylated at two C-terminal 
cysteine residues [40]. It is hypothesized that this palmitoylation plays an important role in NS4B 
oligomerization. However, the role of C-terminal palmitoylation of NS4B in the HCV life cycle 
remains to be further explored.
 
One of the more striking NS4B functions identified to date is its reported effect on intracellular 
membranes. Expression of the HCV NS4B protein alone is sufficient to cause formation of the   
so-called “membranous web” structure [32,37] which is thought to represent the platform upon which 
HCV replication takes places. Like all positive strand RNA viruses, HCV replicates its genome in 
intimate association with intracellular membranes. The membranous web is believed to be derived in 
part from the ER. A number of studies have also suggested that the early endosome proteins Rab5 and 
Rab7 [41,42], phosphatidylinositol 4-kinase III alpha [43] and autophagy protein ATG5 [44] may play 
a role in HCV genome replication or membranous web formation. The membranous web consists of a 
collection of vesicular-like structures detectable by electron microscopy. Under light microscopy, the 




Both N- and C-terminal amphipathic helices have been implicated in the formation of such   
foci [28,31]. The mechanism(s) by which NS4B induces the membranous web, and which host cell 
components are hijacked for this purpose are still largely unknown.  
Site-directed mutagenesis in the replicon and HCVcc systems has demonstrated the essential role of 
NS4B in HCV RNA replication [24,27,28,31,38,46,47]. Jones et al. [38] revealed an additional role of 
NS4B in viral assembly when a single amino acid substitution, N216A, in NS4B was shown to be 
sufficient to increase the titer of JFH1 virus by five-fold without affecting HCV RNA replication. This 
highly conserved position, located between helices H1 and H2, might be critical for interaction 
between NS4B and other components of the viral assembly machinery.  
Physical interactions between NS4B and other nonstructural proteins have been demonstrated by 
glutathione S-transferase pull-down experiments [39]. In addition, intragenotypic interactions between 
NS3 and NS4B were demonstrated in the replicon system [48], which may underlie recent findings of 
synergy between pharmacologic inhibitors of NS3 and NS4B (see Section 3.2. below). 
Another functionality of NS4B was identified by Einav and colleagues, who discovered a functional 
nucleotide-binding motif (NBM) within NS4B. This motif was found to mediate GTP hydrolysis and 
is essential for HCV replication [49]. Thompson et al. confirmed this finding recently and also 
demonstrated ATPase and adenylate kinase activity for NS4B [50]. 
Finally, NS4B has been shown to bind the viral RNA, an interaction that is critical for HCV 
replication [51]. These aspects of NS4B functionality are discussed further, below. 
Figure 1. NS4B membrane topology. Schematic representation of the HCV NS4B protein, 
and its proposed topology with respect to the ER membrane, depicting the N-terminal 
amphipathic helices (AH1, AH2), the four transmembrane domains (TM1-4), and the two 
C-terminal helices (H1, H2). A fraction of NS4B appears to be able to undergo a   
post-translational translocation event wherein the N-terminus of NS4B adopts a luminal 
orientation (indicated by dashed blue arrow), thereby creating a fifth transmembrane 
domain. Walker A and B motifs and RNA binding motif are also indicated. 
 




3. NS4B as an antiviral target  
NS4B is particularly difficult to study due to its integral membrane association. In the following 
sections, we will summarize the potential of some of the above-described features of NS4B as antiviral 
targets and describe recent advancements in the development of new pharmacological approaches for 
inhibiting NS4B functions. 
These pharmacologic inhibitors derive in large part from the above identified functions of NS4B. 
As our knowledge of the latter increases, this list is expected to grow. 
3.1. NTPase activity  
NS4B has been shown to contain a nucleotide binding motif (NBM), with the Walker A motif 
(129GSIGLK135) located between transmembrane domains 2 and 3, and the Walker B motif 
(228DAAA231) located in a central portion of the C-terminus [49,50]. This NBM binds and 
hydrolyses GTP and ATP. The NS4B NBM has also been shown to mediate an adenylate kinase 
activity, which catalyzes the synthesis of ATP and AMP from two ADP molecules [50]. The precise 
role of NS4B’s NTPase activity in the HCV life cycle, however, remains unknown, although it has 
been suggested that NS4B’s GTPase activity might play a role in NS4B-induced cellular 
transformation and tumor formation [52]. The NS4B NBM motif is conserved across all HCV 
genotypes and isolates, highlighting its importance for HCV infectivity in vivo. Introduction of point 
mutations with the NBM can dramatically inhibit RNA genome replication [49], providing strong 
genetic validation that the NBM represents an attractive potential target for anti-HCV therapy. One  
so-called adaptive mutation in the NS4B NBM (K135T) has been reported to enhance replication [53]. 
While the effect of this mutation on NS4B GTPase activity has not been determined, it is interesting to 
note that many host GTPases have a highly conserved T at the corresponding adjacent position of their 
Walker A motif (GX1X2X3X4GKT), whereas the unadapted wild-type NS4B does not (e.g. amino acid 
136 is a V in the genotype 1b replicon) [49]. 
The specificity of NS4B for ATP versus GTP is another interesting area of investigation.   
Einav et al. found NS4B to have a preference for GTP binding [49], while Thompson et al. found ATP 
to be its more active hydrolysis substrate [50]. Thompson et al. showed slow hydrolysis of GTP and 
suggested that this represents the intrinsic hydrolysis of the enzyme and that a yet unknown NS4B 
GTPase activating protein (GAP) [50] might stimulate catalysis.  
The HCV NBM has features that distinguish it from host cell GTP-binding and hydrolyzing 
proteins. In particular, while the amino acids within the NS4B NBM are similar to those found in the 
NBMs of host GTPases, the amino acids immediately flanking the NS4B NBM are highly conserved 
across HCV isolates, yet very different from those found in host cell GTPases [49]. Moreover, T221 of 
NS4B, which corresponds to the so-called PM2 motif that has been implicated in chelating a   
Mg++ ion in available structures of host GTPases, can be mutated without apparent effect on HCV 
replication [54], suggesting that the co-factor requirements for NS4B may be different than for host 
cell GTPases. Thus, pharmacologic inhibition of the enzymatic activity encoded in the NS4B NBM 
might be achievable with a sufficiently favorable therapeutic index. Such an inhibitor might also have 
the additional benefit of potentially reducing malignant transformation, and could be relevant to the 




3.2. RNA binding  
NS4B has been found to bind the 3’ terminus of the negative strand of the HCV genome [51]. One 
means by which this was demonstrated involved the use of a microfluidics device in combination with 
a mechanical button that enhances the detection of intermolecular interactions [51]. This button system 
is known as MITOMI: the mechanical trapping of molecular interactions [55]. Advantages of this 
method include the requirement for very small sample volumes and the ability to express the protein in 
the presence of microsomal membranes, which enables membrane proteins to adopt a more natural 
folding. 
Using this method, a Kd for NS4B RNA binding was determined to be ~3 nM, with a preference for 
the 3’ terminus of the negative sense HCV RNA. This region is predicted to harbor a highly conserved 
secondary structure that is presumably recognized by NS4B. Moreover, specific binding to this region 
suggests that NS4B may play a role in the initiation of progeny plus strand RNA genomes that begin 
their transcription at the 3’ terminus of the negative strand. Highly conserved arginine residues within 
NS4B were predicted to mediate NS4B’s RNA binding activity, and this hypothesis was tested by 
determining the effect of mutating specific arginines to alanines. Such mutations could both abrogate 
RNA binding and HCV genome replication, highlighting the importance of this activity for the viral 
life cycle and providing genetic validation of the potential of NS4B’s RNA binding activity as an 
antiviral target. 
Einav and colleagues then used the above microfluidics platform to perform a high-throughput 
screen for small molecules capable of inhibiting the binding of NS4B to HCV RNA. This screen 
identified the small molecule clemizole hydrochloride, which inhibited NS4B-HCV RNA binding with 
an IC50 of ~24 nM. Cellular-based replication assays subsequently demonstrated the ability of 
clemizole to inhibit HCV replication [51]. Clemizole’s antiviral effect is notably modest, with an EC50 
of 8 µM against HCV genotype 2a. Interestingly, when combined with some of the NS3 protease 
inhibitors in most advanced clinical development (i.e., telaprevir and boceprevir), clemizole exhibits 
dramatic in vitro synergy [56]. This is in contrast to most combinations of anti-HCV agents, which 
generally exhibit additive interactions. The synergy between clemizole and a protease inhibitor was 
found to decrease the emergence of resistant mutations without conferring cross-resistance [56] in the 
HCV replicon system. It is speculated that an interaction between NS4B and NS3, perhaps involving a 
conformational change, is one reason for the observed dramatic synergy between clemizole and the 
NS3 protease inhibitors.  
If the above in vitro synergistic effects are operative in vivo, such clemizole-protease inhibitor 
combinations may represent an ideal foundation for future interferon-free anti-HCV cocktails. Another 
attractive implication of such synergy is the potential to use these protease inhibitors at lower doses in 
patients, where the desired antiviral and anti-resistance effects could be maintained, while decreasing 
the incidence of important toxicities associated with the protease inhibitors (such as severe rash and 
anemia). 
Clemizole hydrochloride is a H1 histamine receptor antagonist that was widely used in the   
1950-60s to treat allergic disorders. One of its hallmarks is that it is very well tolerated [57]. Because 
of its prior excellent safety record, the re-purposing of this drug for treatment of chronic HCV is being 




Finally, the search for clemizole derivatives with increased potency is an active area of research, 
with a number of analogs with increased antiviral activity having already been identified [58].  
3.3. Lipid vesicle aggregation and 4BAH2 oligomerization  
Because formation of the membranous web is essential for HCV replication, but dispensable for the 
host cells, disrupting the molecular machinery employed to establish the membranous web represents 
an attractive potential therapeutic target. As stated above, recent work suggests that a second 
amphipathic helix (AH2) exists within the N-terminus of NS4B [28,30]. This AH has been designated 
(4BAH2) [30]. It spans amino acids 43 to 65 [30] or 42–66 [28] and plays an important role in this 
process. 4BAH2 is notably conserved across all HCV genotypes and isolates. Studies of the interaction 
of 4BAH2 with lipid vesicles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
demonstrate that 4BAH2 mediates both helix oligomerization and specific aggregation of lipid vesicles 
(for example, no such activity was observed with a peptide corresponding to the NS4B AH1 
amphipathic helix). The structures formed by this vesicle aggregating activity are reminiscent of the 
membranous web [30], and we hypothesize that the activity encoded in 4BAH2 may represent a key 
component of the molecular machinery employed by NS4B to establish the membranous web. This 
ability of 4BAH2 to cause lipid vesicle aggregation was also exploited to identify small molecule 
inhibitors of 4BAH2-mediated vesicle aggregation, using a novel high-throughput screen. In this 
screen, a synthetic peptide comprising the 4BAH2 sequence was added to fluorescently labeled lipid 
vesicles in 384-well plates, wherein each well contained a different member of a small molecule 
library. The vesicle aggregating activity of 4BAH2 was monitored by automated fluorescent 
microscopy. Pattern recognition software was then used to quantitate the amount of fluorescent signal 
contained within 4BAH2 induced lipid vesicle aggregates. In this manner, several candidate 
pharmacologic inhibitors of lipid vesicle aggregation were indentified. The specificity of their 
inhibitory activity was confirmed in secondary assays that were based on monitoring aggregate size 
using dynamic light scattering (DLS), in the presence or absence of individual compounds. The most 
potent inhibitory molecules in the DLS assay were then subsequently found to inhibit HCV genome 
replication with EC50s in the nanomolar range [30]. Two compounds were further studied in detail 
using quartz-crystal microbalance and dissipation to monitor the effects of compounds on the 
membrane association of 4BAH2, and atomic force microscopy to monitor the compounds’ effects on 
4BAH2 oligomerization. Interestingly, at least two different mechanisms of inhibition could be 
defined: one compound (“C4”--5-(N-Methyl-N-isobutyl)amiloride) was able to inhibit 4BAH2 
oligomerization while another (“A2”--7-[chloro(difluoro)methyl]-5-furan-2-yl-N-(thiophen-2-
ylmethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide)  was found to inhibit the ability of 4BAH2 to 
associate with membranes [30]. Importantly, clemizole was found to have no activity in the 4BAH2 
vesicle aggregation assay, and the 4BAH2 inhibitors were found to have no effect on NS4B RNA 
binding—suggesting that 4BAH2 inhibitors and NS4B RNA binding inhibitors represent two distinct 
classes of NS4B inhibitors, with different mechanisms of action. Thus, each class can be independent 
components of future anti-HCV cocktails. Consistent with this is the observation that, in vitro, 
clemizole is synergistic with 4BAH2 lipid aggregation inhibitors [58]. Gouttenoire et al. [28] have also 




suggested that this helix is capable of traversing the phospholipid bilayer as a transmembrane domain. 
Because all of 4BAH2 is initially cytosolically oriented, C4 and A2 may thus inhibit the majority of 
4BAH2 that remains on the cytosolic side of the ER membrane in the presence of other NS proteins 
[29] as well as the fraction of 4BAH2 that might be destined for more profound interactions with the 
membrane. Finally, we postulate that just as therapeutics that target AH2’s functionality inhibit HCV 
replication, therapeutics that target AH1 and disrupt its membrane interaction activity will inhibit HCV 
replication. 
4. Conclusions 
The functions of NS4B identified to date have enabled the development of two new classes of  
anti-HCV drugs: one class that interferes with the ability of NS4B to bind HCV RNA; and another that 
inhibits NS4B’s interactions with membranes. Notably, preliminary data suggests that the drugs that 
target these individual functions of NS4B are synergistic. It is expected that these inhibitors will be 
used as a basis for future structure-function studies designed to yield more potent derivatives and 
eventual new clinical candidates. Furthermore, as other functions for NS4B have already been 
identified, (e.g. its ability to hydrolyze NTPs), it is hoped that these too can be targeted by separate 
classes of antivirals. 
Knowledge of the molecular virology of HCV, and the functions of its encoded proteins, has 
allowed for the design of new drugs that directly target HCV. Other than safety and efficacy, the major 
challenges of HCV drug development are the ability to design therapeutics that inhibit all HCV 
genotypes and yet are insensitive to the emergence of drug mutants. One solution to this latter 
challenge is to administer a cocktail of antiviral agents that target different functions in the viral cycle. 
Accordingly, most current clinical trials test a combination of antiviral agents that combine STAT-C 
agents with IFN or RBV. As more and more STAT-C agents emerge, and more efficacy data is 
accumulated, future studies that are able to omit or decrease IFN or RBV may be considered—such an 
approach would hopefully provide even more tolerable and efficacious therapies to fight HCV and its 
complications. 
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